Evidence map›Paper›PMID 37159554›Full record

ArticleThe oncologist2023

Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.

Camila B Xavier, Rudinei Link, Leonília Abreu, Fabiana Bettoni, Fabiane Marson, Pedro A F Galante, Cibele Masotti, Mariane T Amano, Vinicius de Molla, Anamaria A Camargo and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. MosaicFrontiers in oncology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Camila B XavierOncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.ORCID 0000-0002-7203-8011
Rudinei LinkOncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Leonília AbreuMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Fabiana BettoniMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Fabiane MarsonOncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Pedro A F GalanteMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Cibele MasottiMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Mariane T AmanoMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Vinicius de MollaHematology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Anamaria A CamargoMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Paula F AsprinoMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Jorge SabbagaOncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Hospital Sírio-Libanês · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLi-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancers at later ages, who harbored a likely pathogenic TP53 at low allele frequency detected in a blood sample.

methodsThe Molecular Tumor Board committee at our institution revisited the case of a patient who was enrolled in a research protocol for the investigation of genetic conditions associated with neuroendocrine tumors. Clinical, familial, and molecular data were reviewed. The patient received germline testing using a next generation sequencing multi-gene panel and was incidentally found to harbor a TP53 likely pathogenic variant, with 22% of variant allele fraction. Additional samples, including a second blood sample, oral swab, and saliva, were collected for DNA analysis. A new TP53 sequencing round was performed with the attempt to distinguish between a true constitutional germline variant and a somatically acquired variant due to aberrant clonal expansion of bone marrow precursors.

resultsPatient's personal and familial history of cancer did not meet classic nor Chompret LFS criteria. Environmental risk factors for cancer were identified, such as alcohol abuse and tobacco exposure. The TP53 variant initially found in the next-generation sequencing was confirmed by Sanger sequencing in the previous DNA sample extracted from blood for the first analysis and in a second blood sample collected 6 years later. The TP53 variant was not detected in the DNA extracted from the oral swab and saliva samples.

conclusionConsidering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.

Indexed as

Genetic Predisposition to DiseaseLi-Fraumeni SyndromeClonal HematopoiesisGenetic TestingGerm CellsGerm-Line MutationHumansTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID37159554
PMCPMC10322129
OpenAlexW4376121511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.